The present disclosure relates to devices and methods for transcatheter (i.e., performed through the lumen of a catheter) Glenn shunt and Fontan systems (transcatheter cavopulmonary bypass endograft prosthesis and delivery) for nonsurgical, percutaneous extra-anatomic bypass between two adjacent vessels.
Children born with single ventricle physiology (SVP), a form of cyanotic congenital heart disease (CCHD), represent 7.7% of all congenital heart disease patients and have a birth incidence of approximately 4-8 per 10,000. In the United States, this represents approximately 2,000 children born each year. Currently, SVP infants undergo a series of staged surgical procedures. The first palliative procedure establishes a balance between systemic and pulmonary output while minimizing the overload on the single ventricle. The following palliative procedure is often cavopulmonary anastomosis through a bidirectional Glenn shunt or hemi-Fontan procedure to allow for passive pulmonary bloodflow. These are surgical procedures that are invasive and traumatic, requiring significant recuperation time and excessive burden on such a young patient.
The purpose and advantages of the present disclosure will be set forth in and become apparent from the description that follows. Additional advantages of the disclosed embodiments will be realized and attained by the methods and systems particularly pointed out in the written description hereof, as well as from the appended drawings.
A transcatheter approach for obtaining the results of the surgical procedures described above can revolutionize the management of these children with congenital heart disease. As an alternative to the Norwood Procedure, Bi-directional Glenn operation and Fontan procedure, a nonsurgical transcatheter intervention can limit the burden of surgery for infants while also reducing cost. There is a considerable unmet need for a purpose-built cavopulmonary anastomosis device. To Applicant's knowledge no commercial alternatives exist for off-label medical use.
To achieve these and other advantages and in accordance with the purpose of the disclosure, as embodied herein, in one aspect, the disclosure includes embodiments of a cavopulmonary self-expanding implant to permit an interventional cardiologist to create a shunt between the Superior Vena Cava (SVC) and the main pulmonary artery (MPA). The implant can provide an urgently needed option for children with congenital heart failure to avoid the burden of a three-stage surgery (so called palliative surgery), the burden of an additional heart transplantation after failure of the palliative surgeries, or of the lifelong medication intake after direct heart transplantation.
In some implementations, a radially self-expanding endograft prosthesis is provided that includes (i) distal flange that is self-expanding and configured to flip generally perpendicularly with respect to a body of the prosthesis to help seat the prosthesis against a tissue wall, (ii) a distal segment extending proximally from the distal flange that has sufficient stiffness to maintain a puncture open that is formed through a vessel wall (iii) a compliant middle segment extending proximally from the distal segment, the middle segment being more compliant than the distal segment, and having independently movable undulating strut rings attached to a tubular fabric, the combined structure providing flexibility and compliance to allow for full patency while flexed, the segment being configured to accommodate up to a 90 degree bend, (iv) a proximal segment having a plurality of adjacent undulating strut rings that are connected to each other, the proximal segment being sufficiently stiff to seat within and urge against a vessel wall, and (v) a proximal end including a plurality of openings around the proximal end for accommodating a tether that is threaded through the openings to cause the prosthesis to collapse radially inwardly when tension is applied to the tether.
In some implementations, a delivery system is provided including the prosthesis as set forth above, wherein the prosthesis is mounted on a longitudinal inner member and inside of a retractable sheath. Both ends of the tether that is routed through the prosthesis can extend proximally through and out of a proximal region of the delivery system. The delivery system can further include a first set of radiopaque markers near the distal end of the delivery system, and a second set of markers that are visible outside the patient during a procedure that indicates the relative position of the delivery system and prosthesis, wherein the first and second set of markers are maintained in registration with each other during the procedure. The first set of markers can be located on a distal atraumatic tip of the delivery system made of iron oxide to facilitate navigation under MRI or other imaging modality to position the delivery system accurately, and the second set of markers can indicate the relative longitudinal position of the portions of the delivery system. The markers can be configured to indicate when the distal flange of the prosthesis is suitably configured to pull against an inner face of the wall of an artery, such as main pulmonary artery.
The prosthesis can further include a flared or bell-shaped proximal region to enhance apposition against the interior wall of a lumen. The prosthesis can further define at least one fenestration through a sidewall thereof to permit leakage of bodily fluid through the fenestration.
In some implementations, a tubular prosthesis is provided having a first flanged end and a second flanged end, each flanged end being configured to urge against an inner surface of a first body lumen and a second body lumen when the prosthesis is mounted through openings formed into the walls of the first body lumen and second body lumen. The prosthesis can be adjusted in length. The prosthesis can include proximal and distal portions connected by a central elastic region such that the prosthesis can be stretched to cause the flanged ends of the prosthesis to pull against the lumens that the flanged ends are mounted into.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and are intended to provide further explanation of the embodiments disclosed herein.
The accompanying drawings, which are incorporated in and constitute part of this specification, are included to illustrate and provide a further understanding of the method and system of the disclosure. Together with the description, the drawings serve to explain the principles of the disclosed embodiments.
The foregoing and other objects, aspects, features, and advantages of exemplary embodiments will become more apparent and may be better understood by referring to the following description taken in conjunction with the accompanying drawings, in which:
Reference will now be made in detail to the present preferred embodiments of the disclosure, examples of which are illustrated in the accompanying drawings. The method and corresponding steps of the disclosed embodiments will be described in conjunction with the detailed description of the system. The exemplary embodiments illustrated herein can be used to perform Glenn and Fontan procedures, but percutaneously. It will be appreciated, however, that the disclosed embodiments, or variations thereof, can be used for a multitude of procedures involving the connection of blood vessels or other biological lumens to native or artificial structures.
Embodiments of a disclosed TCBE (Transcatheter Cavopulmonary Bypass Endograft) represent a potential breakthrough for physicians and young patients who require a safe, less-burdensome, and effective alternative to open heart surgery: a percutaneous approach to heal congenital heart failure.
In particular implementations, the underlying design of the TCBE is based on four components: (i) a distal segment, which is divided into a flange (consisting of a multi-pointed (e.g., six-pointed) star) and two to four rows of connected (e.g., by stitching) undulating wire segments; (ii) a middle segment, which includes longer non-connected undulating wire segments, (iii) and the largest, proximal, segment, which is useful for bridging and stabilization of the implant in the vessel. Depending on the size of the implant, it can be built as a “Glenn Shunt” (about 5 cm in length) or a “Fontan Shunt” (about 8 cm in length). These can be, for example, super elastic Nitinol-supported tubular polyester fabric implants that are delivered through a specially designed delivery system. Preferably, the prosthesis and delivery system are both MRI compatible. The illustrated TCBE embodiments can incorporate several useful features specifically developed for transcatheter cavopulmonary bypass.
For purposes of illustration, and not limitation, as embodied herein and as illustrated in
As can be seen, the proximal end of the prosthesis receives a tether therethrough that is routed through the windings of the undulating ring. The tethers are withdrawn proximally through a tubular member (e.g., a sheath) that also passes a core member therethrough that forms the core, or push rod of the delivery system. The core is slidably disposable with respect to the sheath. By advancing the core member with the prosthesis mounted thereto distally outwardly of the sheath, the prosthesis self-expands. However, if the tether is tensioned, it causes the proximal end of the prosthesis to collapse radially inwardly such that the prosthesis can be withdrawn into the sheath. While adjacent undulating rings of the prosthesis particularly near the distal end of the prosthesis can be connected to each other (e.g., by sewing), they can also be kept independent of one another, and be attached to an inner and/or outer tubular fabric layer. The rigidity of the prosthesis is selected and/or configured to provide a desired performance. Thus, the distal end is relatively rigid to maintain an opening in the wall of a vessel or other organ in an open state that the prosthesis traverses through by resisting the force of the vessel wall to want to “close” the hole in itself. The proximal region is less rigid and can accommodate increasing vessel curvature of the vessel that it is mounted in.
The delivery system typically includes an atraumatic distal tip that can pass a guidewire therethrough, and may be provided with one or more radiopaque markers to facilitate visualization under fluoroscopy, for example. The distal end or end region of the sheath of the delivery system (that surrounds the prosthesis when loaded onto the delivery system) can also include a radiopaque marker.
The star shaped flange on the end of each prosthesis helps the prosthesis seat well within the vasculature. In some embodiments the tethers can be routed through parallel lumens along the length of the delivery system to prevent them from tangling with each other. The prosthesis for the Fontan procedure preferably includes a proximal region that flares out, as illustrated in
Generally, during deployment, the delivery system is advanced to a position where the prosthesis should be deployed. The distal tip and core of the guidewire are then advanced distally as well as the prosthesis, and the prosthesis flange is deployed thorough an opening in a wall of a vessel or other tissue wall. The flanged end then urges against the inner wall of the vessel. A corresponding marker can be used on the proximal end of the delivery system to show at what point of relative advancement the flange has been deployed. The delivery system is then pulled proximally slightly to seat the flange. When satisfied with seating, the user holds the inner shaft of the delivery system and pulls back on outer sheath to release the entire implant. The tether can then be de-tensioned to open the proximal end of implant. Finally, the user can pull on one end of the tether to remove it from the implant, and the delivery system can be removed. However, if desired, prior to removal of the tether, the tether can be re-tensioned, causing the proximal end of the prosthesis to collapse radially inwardly, and the prosthesis can be withdrawn into the sheath of the delivery system, and removed.
The devices and methods disclosed herein can be used for other procedures in an as-is condition, or can be modified as needed to suit the particular procedure. In view of the many possible embodiments to which the principles of this disclosure may be applied, it should be recognized that the illustrated embodiments are only preferred examples of the disclosure and should not be taken as limiting the scope of the disclosure.
The present patent application is a continuation of and claims the benefit of priority to U.S. patent application Ser. No. 16/399,670, filed Apr. 30, 2019, which is a continuation of and claims the benefit of priority to U.S. patent application Ser. No. 15/267,075, filed Sep. 15, 2016, now U.S. Pat. No. 10,426,482, which in turn claims the benefit of priority to U.S. Provisional Patent Application Ser. No. 62/219,118, filed Sep. 15, 2015, and U.S. Provisional Patent Application Ser. No. 62/363,716, filed Jul. 18, 2016. Each of the foregoing patent applications is incorporated by reference herein for any purpose whatsoever.
Number | Name | Date | Kind |
---|---|---|---|
4106129 | Carpentier et al. | Aug 1978 | A |
4259753 | Liotta et al. | Apr 1981 | A |
4666442 | Arru et al. | May 1987 | A |
4692164 | Dzemeshkevich et al. | Sep 1987 | A |
5411552 | Andersen et al. | May 1995 | A |
5449384 | Johnson | Sep 1995 | A |
5606928 | Religa et al. | Mar 1997 | A |
5639278 | Dereume et al. | Jun 1997 | A |
5749921 | Lenker et al. | May 1998 | A |
5788715 | Watson, Jr. et al. | Aug 1998 | A |
5861028 | Angell | Jan 1999 | A |
5895410 | Forber et al. | Apr 1999 | A |
5928281 | Huynh et al. | Jul 1999 | A |
6059769 | Lunn et al. | May 2000 | A |
6090136 | McDonald | Jul 2000 | A |
6106510 | Lunn et al. | Aug 2000 | A |
6238430 | Klumb et al. | May 2001 | B1 |
6375774 | Lunn et al. | Apr 2002 | B1 |
6599303 | Peterson | Jul 2003 | B1 |
6602271 | Adams et al. | Aug 2003 | B2 |
6716231 | Rafiee et al. | Apr 2004 | B1 |
6733525 | Yang et al. | May 2004 | B2 |
6790229 | Berreklouw | Sep 2004 | B1 |
6797000 | Simpson et al. | Sep 2004 | B2 |
6800081 | Parodi | Oct 2004 | B2 |
6866677 | Douk et al. | Mar 2005 | B2 |
6911036 | Douk et al. | Jun 2005 | B2 |
6926690 | Renati | Aug 2005 | B2 |
6953476 | Shalev | Oct 2005 | B1 |
6960217 | Bolduc | Nov 2005 | B2 |
7044958 | Douk et al. | May 2006 | B2 |
7066946 | Douk et al. | Jun 2006 | B2 |
7137993 | Acosta | Nov 2006 | B2 |
7189259 | Simionescu et al. | Mar 2007 | B2 |
7195641 | Palmaz et al. | Mar 2007 | B2 |
7201772 | Schwammenthal et al. | Apr 2007 | B2 |
7294135 | Stephens et al. | Nov 2007 | B2 |
7316706 | Bloom et al. | Jan 2008 | B2 |
7399315 | Iobbi | Jul 2008 | B2 |
7425219 | Quadri | Sep 2008 | B2 |
7442204 | Schwammenthal et al. | Oct 2008 | B2 |
7442207 | Rafiee | Oct 2008 | B2 |
7445631 | Salahieh et al. | Nov 2008 | B2 |
7481838 | Carpentier et al. | Jan 2009 | B2 |
7491232 | Bolduc et al. | Feb 2009 | B2 |
7524330 | Berreklouw | Apr 2009 | B2 |
7655040 | Douk et al. | Feb 2010 | B2 |
7682352 | Rafiee et al. | Mar 2010 | B2 |
7699892 | Rafiee et al. | Apr 2010 | B2 |
7716801 | Douk et al. | May 2010 | B2 |
7753840 | Simionescu et al. | Jul 2010 | B2 |
7753949 | Lamphere et al. | Jul 2010 | B2 |
7780726 | Seguin | Aug 2010 | B2 |
7799069 | Bailey et al. | Sep 2010 | B2 |
7806917 | Xiao | Oct 2010 | B2 |
7806919 | Bloom et al. | Oct 2010 | B2 |
7815673 | Bloom et al. | Oct 2010 | B2 |
7947072 | Yang et al. | May 2011 | B2 |
7955384 | Rafiee et al. | Jun 2011 | B2 |
7972370 | Douk et al. | Jul 2011 | B2 |
7998188 | Zilla et al. | Aug 2011 | B2 |
8002825 | Letac et al. | Aug 2011 | B2 |
8052750 | Tuval et al. | Nov 2011 | B2 |
8062355 | Figulla et al. | Nov 2011 | B2 |
8070802 | Lamphere et al. | Dec 2011 | B2 |
8092518 | Schreck | Jan 2012 | B2 |
8092520 | Quadri | Jan 2012 | B2 |
8092524 | Nugent et al. | Jan 2012 | B2 |
8226710 | Nguyen et al. | Jul 2012 | B2 |
8252051 | Chau et al. | Aug 2012 | B2 |
8308798 | Pintor et al. | Nov 2012 | B2 |
8337541 | Quadri et al. | Dec 2012 | B2 |
8348995 | Tuval et al. | Jan 2013 | B2 |
8348996 | Tuval et al. | Jan 2013 | B2 |
8353954 | Cai et al. | Jan 2013 | B2 |
8353955 | Styrc et al. | Jan 2013 | B2 |
8518096 | Nelson | Aug 2013 | B2 |
10426482 | Rafiee et al. | Oct 2019 | B2 |
11179156 | Rafiee | Nov 2021 | B2 |
20010021872 | Bailey et al. | Sep 2001 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020138138 | Yang | Sep 2002 | A1 |
20030055495 | Pease et al. | Mar 2003 | A1 |
20030065386 | Weadock | Apr 2003 | A1 |
20030097172 | Shalev et al. | May 2003 | A1 |
20040087998 | Lee et al. | May 2004 | A1 |
20040127916 | Bolduc et al. | Jul 2004 | A1 |
20050038508 | Gabbay | Feb 2005 | A1 |
20050043790 | Seguin | Feb 2005 | A1 |
20050049675 | Wallace | Mar 2005 | A1 |
20050055082 | Ben-Muvhar et al. | Mar 2005 | A1 |
20050137769 | Salahieh et al. | Jun 2005 | A1 |
20050143809 | Salahieh et al. | Jun 2005 | A1 |
20050177180 | Kaganov et al. | Aug 2005 | A1 |
20050288706 | Widomski et al. | Dec 2005 | A1 |
20060085012 | Dolan | Apr 2006 | A1 |
20060106449 | Ben-Muvhar | May 2006 | A1 |
20060106450 | Ben-Muvhar | May 2006 | A1 |
20060173537 | Yang et al. | Aug 2006 | A1 |
20070043435 | Seguin et al. | Feb 2007 | A1 |
20070067029 | Gabbay | Mar 2007 | A1 |
20070250160 | Rafiee | Oct 2007 | A1 |
20070255398 | Yang et al. | Nov 2007 | A1 |
20070288089 | Gurskis et al. | Dec 2007 | A1 |
20070293942 | Mizraee | Dec 2007 | A1 |
20080015687 | Lashinski et al. | Jan 2008 | A1 |
20080021537 | Ben-Muvhar et al. | Jan 2008 | A1 |
20080065191 | Bolduc et al. | Mar 2008 | A1 |
20080077234 | Styrc | Mar 2008 | A1 |
20080125860 | Webler et al. | May 2008 | A1 |
20080208328 | Antocci et al. | Aug 2008 | A1 |
20080221672 | Lamphere et al. | Sep 2008 | A1 |
20090005863 | Goetz et al. | Jan 2009 | A1 |
20090062841 | Amplatz et al. | Mar 2009 | A1 |
20090270966 | Douk et al. | Oct 2009 | A1 |
20090270976 | Douk et al. | Oct 2009 | A1 |
20090306768 | Quadri | Dec 2009 | A1 |
20090319038 | Gurskis et al. | Dec 2009 | A1 |
20100036479 | Hill et al. | Feb 2010 | A1 |
20100082094 | Quadri et al. | Apr 2010 | A1 |
20100100167 | Bortlein et al. | Apr 2010 | A1 |
20100174363 | Castro | Jul 2010 | A1 |
20100179648 | Richter et al. | Jul 2010 | A1 |
20100179649 | Richter et al. | Jul 2010 | A1 |
20100185275 | Richter et al. | Jul 2010 | A1 |
20100249923 | Alkhatib et al. | Sep 2010 | A1 |
20100262232 | Annest | Oct 2010 | A1 |
20100280606 | Naor | Nov 2010 | A1 |
20100298931 | Quadri et al. | Nov 2010 | A1 |
20110112632 | Chau et al. | May 2011 | A1 |
20110137409 | Yang et al. | Jun 2011 | A1 |
20110172784 | Richter et al. | Jul 2011 | A1 |
20110282438 | Drews et al. | Nov 2011 | A1 |
20110313515 | Quadri et al. | Dec 2011 | A1 |
20110319988 | Schankereli et al. | Dec 2011 | A1 |
20110319989 | Lane et al. | Dec 2011 | A1 |
20120022639 | Hacohen | Jan 2012 | A1 |
20120059450 | Chiang et al. | Mar 2012 | A1 |
20120065652 | Cully et al. | Mar 2012 | A1 |
20120078353 | Quadri et al. | Mar 2012 | A1 |
20120078360 | Rafiee | Mar 2012 | A1 |
20120143141 | Verkaik | Jun 2012 | A1 |
20120179244 | Schankereli et al. | Jul 2012 | A1 |
20120215303 | Quadri et al. | Aug 2012 | A1 |
20120316642 | Yu et al. | Dec 2012 | A1 |
20120323316 | Chau et al. | Dec 2012 | A1 |
20140018906 | Rafiee | Jan 2014 | A1 |
20140128965 | Rafiee | May 2014 | A1 |
20140163668 | Rafiee | Jun 2014 | A1 |
20140358223 | Rafiee et al. | Dec 2014 | A1 |
20140039083 | Rafiee | Feb 2015 | A1 |
20150134051 | Donadio et al. | May 2015 | A1 |
20190231510 | Rafiee et al. | Aug 2019 | A1 |
Number | Date | Country |
---|---|---|
2412397 | Feb 2012 | EP |
2015519969 | Jul 2015 | JP |
20130110413 | Oct 2013 | KR |
101501614 | Mar 2015 | KR |
100 718 | Dec 2010 | RU |
WO2007121314 | Oct 2007 | WO |
WO2012061809 | May 2012 | WO |
WO2013131069 | Sep 2013 | WO |
WO2015069947 | May 2015 | WO |
WO2015148821 | Oct 2015 | WO |
Entry |
---|
International Search Report dated Jun. 16, 2022 in International Patent Application No. PCT/US2022/018806. |
Written Opinion of the International Searching Authority dated May 17, 2022 in International Patent Application No. PCT/US2022/018806. |
International Search Report, for related application No. PCT/US2011/059586, dated May 25, 2012. |
International Preliminary Report on Patentability and Written Opinion, or related application No. PCT/US2011/059586, dated May 25, 2012. |
BioIntegral Surgical, Mitral Valve Restoration System. |
International Search Report for co-pending international application No. PCT/US2013/028774, dated Jun. 14, 2013. |
International Preliminary Report on Patentability and Written Opinion, on related application No. PCT/US2014/064431 dated Mar. 26, 2015. |
International Search Report, for related application No. PCT/US2015/022782, dated Jun. 18, 2015. |
International Search Report and Written Opinion in Application No. PCT/US2016/052005, dated Dec. 29, 2016. |
International Search Report and Written Opinion in Application No. PCT/US2018/049373, dated Dec. 6, 2018. |
Office Action in related Japanese Patent Application No. JP2018-514884 dated Jun. 30, 2020 with English language translation. |
Number | Date | Country | |
---|---|---|---|
20220125430 A1 | Apr 2022 | US |
Number | Date | Country | |
---|---|---|---|
62363716 | Jul 2016 | US | |
62219118 | Sep 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16399670 | Apr 2019 | US |
Child | 17462190 | US | |
Parent | 15267075 | Sep 2016 | US |
Child | 16399670 | US |